Published in Clin Endocrinol (Oxf) on January 01, 2011
Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol (2012) 1.12
Autoimmunity and Graves' disease. Clin Pharmacol Ther (2012) 0.95
Is Thyroid Autoimmunity per se a Determinant of Quality of Life in Patients with Autoimmune Hypothyroidism? Eur Thyroid J (2012) 0.88
Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev Clin Pharmacol (2012) 0.88
Relevance of TSH-receptor antibody levels in predicting disease course in Graves' orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay. Eye (Lond) (2013) 0.81
Thyroid-associated Ophthalmopathy. Turk J Ophthalmol (2017) 0.75
Rituximab therapy in steroid-resistant severe hypothyroid Grave's ophthalmopathy. Indian J Endocrinol Metab (2013) 0.75
Impact of methimazole treatment on magnesium concentration and lymphocytes activation in adolescents with Graves' disease. Biol Trace Elem Res (2013) 0.75
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Antigen-specific interaction between T and B cells. Nature (1985) 10.64
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
B cells regulate autoimmunity by provision of IL-10. Nat Immunol (2002) 7.30
Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med (2009) 6.89
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Clinical practice. Graves' disease. N Engl J Med (2008) 5.78
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Prevention of arthritis by interleukin 10-producing B cells. J Exp Med (2003) 4.27
Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev (2008) 3.67
Graves' disease. N Engl J Med (2000) 3.50
B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med (1996) 3.35
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
T cell activation in rheumatoid synovium is B cell dependent. J Immunol (2001) 2.73
B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol (1998) 2.63
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) (2001) 2.45
Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology (2009) 2.44
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab (2001) 2.10
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab (2007) 1.84
B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol (1998) 1.81
Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis (2002) 1.74
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood (2009) 1.71
Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid (1991) 1.66
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol (2003) 1.66
B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum (2006) 1.65
Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol (2008) 1.64
Clinical practice. Graves' ophthalmopathy. N Engl J Med (2009) 1.63
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (2006) 1.60
Rituximab in relapsing Graves' disease, a phase II study. Eur J Endocrinol (2008) 1.59
B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1. J Immunol (2003) 1.56
Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) (2006) 1.53
Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol (2001) 1.52
Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis (2007) 1.48
Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab (2004) 1.45
Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum (2007) 1.38
Dendritic cell-derived IL-12 promotes B cell induction of Th2 differentiation: a feedback regulation of Th1 development. J Immunol (1999) 1.36
Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol (2007) 1.35
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut (2008) 1.28
Interleukin 4 induces selective production of interleukin 6 from normal human B lymphocytes. J Exp Med (1989) 1.26
Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol (2006) 1.25
Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab (2009) 1.24
Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology (1999) 1.22
Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy. Clin Endocrinol (Oxf) (2005) 1.19
Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol (2008) 1.14
IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology (1999) 1.10
Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol (2008) 1.09
B-cell depletion with rituximab in the treatment of autoimmune diseases. Graves' ophthalmopathy the latest addition to an expanding family. Expert Opin Biol Ther (2007) 1.07
A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) (2008) 1.04
Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4(+) T cells in healthy individuals. Eur J Immunol (2001) 1.01
Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. Eur J Immunol (2004) 1.01
Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid (2006) 1.01
Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol (2006) 1.00
Treatment of Graves' hyperthyroidism: evidence-based and emerging modalities. Endocrinol Metab Clin North Am (2009) 0.95
Immune complexes present in the sera of autoimmune mice activate rheumatoid factor B cells. J Immunol (2000) 0.94
Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 0.92
Long-lived plasma cells in immunity and immunopathology. Immunol Lett (2005) 0.92
Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin Endocrinol (Oxf) (2009) 0.87
Evidence for antigen presentation to sensitized T cells by thyroid peroxidase (TPO)-specific B cells in mice injected with fibroblasts co-expressing TPO and MHC class II. Clin Exp Immunol (2000) 0.83
B cell depletion in Graves' disease: the right answer to the wrong question? J Clin Endocrinol Metab (2007) 0.82
B-cell depletion with rituximab-a targeted therapy for Graves' disease and autoimmune thyroiditis. Immunol Lett (2003) 0.81
Targeting B cells in Graves' disease. Endocrinology (2006) 0.81
Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. Arch Ophthalmol (2009) 0.79
Differences in thyroid-infiltrating B lymphocytes in patients with Graves' disease: relationship to autoantibody detection. Thyroid (2004) 0.79
Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy. Acta Ophthalmol (2009) 0.79
Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves' disease. J Clin Endocrinol Metab (2007) 0.79
Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network. Clin Immunol (2009) 0.78
Clinical images: B cell depletion in the appendix following rituximab treatment. Arthritis Rheum (2006) 0.76
Optimizing remission rates using antithyroid drugs for Graves' disease. Clin Endocrinol (Oxf) (2009) 0.76
Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology (2011) 2.86
Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology (2009) 2.44
Comparing outcomes of enucleation and evisceration. Ophthalmology (2006) 2.30
Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev (2003) 2.23
Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab (2009) 2.10
The hydrogel lacrimal stent for dacryocystorhinostomy: preliminary experience. Ophthal Plast Reconstr Surg (2008) 2.01
B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. J Clin Endocrinol Metab (2007) 1.84
Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Am J Pathol (2003) 1.75
T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology (2008) 1.59
Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol (2003) 1.51
Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol (2008) 1.45
Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy. Arch Ophthalmol (2012) 1.40
Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis. N Engl J Med (2015) 1.39
Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol (2002) 1.36
Improved detection of DNA motifs using a self-organized clustering of familial binding profiles. Bioinformatics (2005) 1.29
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut (2008) 1.28
Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol (2002) 1.26
Isolation and phenotypic characterization of lung fibroblasts. Methods Mol Med (2005) 1.24
Integrated microfluidic tmRNA purification and real-time NASBA device for molecular diagnostics. Lab Chip (2008) 1.22
More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest (2006) 1.21
Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid (2008) 1.21
Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol (2007) 1.20
IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol (2005) 1.18
GABA(A) receptor function is regulated by lipid bilayer elasticity. Biochemistry (2006) 1.15
Differences in bacterial saliva profile between periodontitis patients and a control cohort. J Clin Periodontol (2013) 1.14
Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol (2002) 1.14
Interfacial tryptophan residues: a role for the cation-pi effect? Biophys J (2005) 1.11
Transcription factor binding site identification using the self-organizing map. Bioinformatics (2005) 1.11
Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol (2010) 1.11
Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest Ophthalmol Vis Sci (2008) 1.10
Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol (2008) 1.09
Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production. J Clin Endocrinol Metab (2012) 1.08
Oxytocic plant cyclotides as templates for peptide G protein-coupled receptor ligand design. Proc Natl Acad Sci U S A (2013) 1.07
Immune mechanisms in thyroid eye disease. Thyroid (2008) 1.05
Fibroblasts expressing the thyrotropin receptor overarch thyroid and orbit in Graves' disease. J Clin Endocrinol Metab (2011) 1.05
Inhibitory effect of leptin on human uterine contractility in vitro. Am J Obstet Gynecol (2006) 1.04
Modulation of human uterine smooth muscle cell collagen contractility by thrombin, Y-27632, TNF alpha and indomethacin. Reprod Biol Endocrinol (2009) 1.03
Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci (2014) 1.03
Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab (2012) 1.01
Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid (2006) 1.01
Facial recontouring with autogenous fat. Facial Plast Surg (2004) 1.01
Endoscopic removal of nasoglabellar dermoid cysts. Ophthal Plast Reconstr Surg (2010) 1.00
Activated platelets enhance IL-10 secretion and reduce TNF-α secretion by monocytes. J Immunol (2013) 0.99
Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. Ann Surg (2014) 0.99
Cytokines, Graves' disease, and thyroid-associated ophthalmopathy. Thyroid (2008) 0.99
Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc Natl Acad Sci U S A (2012) 0.97
B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol (2008) 0.96
Synovial fibroblasts from patients with rheumatoid arthritis, like fibroblasts from Graves' disease, express high levels of IL-16 when treated with Igs against insulin-like growth factor-1 receptor. J Immunol (2004) 0.96
Interleukin-4 induces 15-lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence for anatomic site-selective actions of Th2 cytokines. J Biol Chem (2006) 0.95
Treating the thyroid in the presence of Graves' ophthalmopathy. Best Pract Res Clin Endocrinol Metab (2012) 0.94
Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am J Physiol Cell Physiol (2003) 0.94
Interleukin-6 production in CD40-engaged fibrocytes in thyroid-associated ophthalmopathy: involvement of Akt and NF-κB. Invest Ophthalmol Vis Sci (2012) 0.94
"En-glove" lysis of lower eyelid retractors with AlloDerm and dermis-fat grafts in lower eyelid retraction surgery. Ophthal Plast Reconstr Surg (2011) 0.94
PGE2 induces IL-6 in orbital fibroblasts through EP2 receptors and increased gene promoter activity: implications to thyroid-associated ophthalmopathy. PLoS One (2010) 0.93
Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. J Endocrinol (2011) 0.93
Does a causal relation between cardiovascular disease and periodontitis exist? Microbes Infect (2011) 0.93
Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions. PLoS One (2013) 0.92
Treatment of lower eyelid retraction by expansion of the lower eyelid with hyaluronic Acid gel. Ophthal Plast Reconstr Surg (2007) 0.91
Divergent Sp1 protein levels may underlie differential expression of UDP-glucose dehydrogenase by fibroblasts: role in susceptibility to orbital Graves disease. J Biol Chem (2011) 0.91
Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab (2014) 0.90
Efficacy of corticosteroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol (2007) 0.90
Evaluation of human endothelial cells post stent deployment in a cardiovascular simulator in vitro. Ann Biomed Eng (2009) 0.90
Use of hyaluronic Acid gel in the management of paralytic lagophthalmos: the hyaluronic Acid gel "gold weight". Ophthal Plast Reconstr Surg (2009) 0.89
The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. Eur J Endocrinol (2006) 0.89
Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management. Saudi J Ophthalmol (2010) 0.89
Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology (2006) 0.88
Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen. Arthritis Res Ther (2014) 0.88
Rosiglitazone-induced proptosis. Arch Ophthalmol (2005) 0.88
Analysis of Maxi-K alpha subunit splice variants in human myometrium. Reprod Biol Endocrinol (2004) 0.88
The atherogenic bacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes. Infect Immun (2011) 0.88
The pathophysiology of thyroid eye disease. J Neuroophthalmol (2014) 0.88
Rho A/Rho kinase mRNA and protein levels in human myometrium during pregnancy and labor. J Soc Gynecol Investig (2005) 0.87
Long-term exposure of CdTe quantum dots on PC12 cellular activity and the determination of optimum non-toxic concentrations for biological use. J Nanobiotechnology (2010) 0.87
Expression of prothrombin and protease activated receptors in human myometrium during pregnancy and labor. Biol Reprod (2007) 0.87
Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. Immunology (2008) 0.87
Aesthetic lateral canthoplasty. Ophthal Plast Reconstr Surg (2010) 0.87
Molecular cloning of an IL-8-like CXC chemokine and tissue factor in rainbow trout (Oncorhynchus mykiss) by use of suppression subtractive hybridization. Cytokine (2002) 0.86
Orbital wall fracture repair using Seprafilm. Ophthal Plast Reconstr Surg (2009) 0.86
Biomimetic triblock copolymer membrane arrays: a stable template for functional membrane proteins. Langmuir (2009) 0.86
Human chorionic gonadotrophin relaxation of human pregnant myometrium and activation of the BKCa channel. J Clin Endocrinol Metab (2003) 0.86
Uterine contractility of plants used to facilitate childbirth in Nigerian ethnomedicine. J Ethnopharmacol (2012) 0.86
Functional coupling of beta3-adrenoceptors and large conductance calcium-activated potassium channels in human uterine myocytes. J Clin Endocrinol Metab (2005) 0.86
Induction by IL-1 beta of tissue inhibitor of metalloproteinase-1 in human orbital fibroblasts: modulation of gene promoter activity by IL-4 and IFN-gamma. J Immunol (2005) 0.86
Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult Scler (2010) 0.86
Divergent expression of IL-1 receptor antagonists in CD34⁺ fibrocytes and orbital fibroblasts in thyroid-associated ophthalmopathy: contribution of fibrocytes to orbital inflammation. J Clin Endocrinol Metab (2013) 0.85